Moleculin Biotech

Yahoo Finance • last month

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial HOUSTON, Dec. 09, 2... Full story

Yahoo Finance • last month

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech... Full story

Yahoo Finance • 2 months ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late... Full story

Yahoo Finance • 2 months ago

Moleculin Announces Reverse Stock Split

Moleculin Biotech, Inc. HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation... Full story

Yahoo Finance • 2 months ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (... Full story

Yahoo Finance • 2 months ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Annamycin targets key factors in pancreatic... Full story

Yahoo Finance • 2 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral in... Full story

Yahoo Finance • 3 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral in... Full story

Yahoo Finance • 3 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 4 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral i... Full story

Yahoo Finance • 4 months ago

Moleculin Biotech files to sell 64.86M shares of common stock by selling shareholder

* Moleculin Biotech (NASDAQ:MBRX [https://seekingalpha.com/symbol/MBRX]) filed to sell 64.86 million common stock. * This prospectus is not an offer to sell these securities. * The company will not receive any proceeds from the sale... Full story

Yahoo Finance • 4 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

European expansion in September across Georgia, Italy, Lithuania, Poland, Romania, Spain, and US 13 subjects recruited (treated, enrolled, or screened) Forecasts total recruitment of 20 or more subjects by end of September On track to r... Full story

Yahoo Finance • 4 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or th... Full story

Yahoo Finance • 5 months ago

Thursday's session: top gainers and losers

Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE... Full story

Yahoo Finance • 5 months ago

Let's take a look at the stocks that are in motion in today's session.

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SOGP [https://www.cha... Full story

Yahoo Finance • 5 months ago

The market is filled with gapping stocks in Thursday's session.

In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SOGP [https://www.chartmill.com/stock/qu... Full story

Yahoo Finance • 5 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses,... Full story

Yahoo Finance • 5 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L-7L) of 9 months (n=22) OS demonstrat... Full story

Yahoo Finance • 5 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

– Live video webcast on Wednesday, August 20th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio o... Full story

Yahoo Finance • 5 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3 - Anticipated data readout of MIRACLE Part A targete... Full story